Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.

Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F.

Breast Cancer Res. 2019 Jul 5;21(1):78. doi: 10.1186/s13058-019-1154-8.

2.

Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation.

Jaeger AM, Stopfer L, Lee S, Gaglia G, Sandel D, Santagata S, Lin NU, Trepel JB, White F, Jacks T, Lindquist S, Whitesell L.

Clin Cancer Res. 2019 Jun 18. doi: 10.1158/1078-0432.CCR-19-0596. [Epub ahead of print]

PMID:
31213460
3.

Barriers to Accrual and Enrollment in Brain Tumor Trials.

Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jun 7. pii: noz104. doi: 10.1093/neuonc/noz104. [Epub ahead of print]

PMID:
31175826
4.

Correction to: Systemic Therapy of Central Nervous System Metastases of Breast Cancer.

Leone JP, Lin NU.

Curr Oncol Rep. 2019 May 17;21(7):59. doi: 10.1007/s11912-019-0813-3.

PMID:
31098730
5.

Prognostic Value of Brain Metastasis-Free Interval in Patients with Breast Cancer Brain Metastases.

Hulsbergen AFC, Lamba N, Claes A, Kavouridis VK, Lin NU, Smith TR, Verhoeff JJC, Broekman MLD.

World Neurosurg. 2019 Apr 26. pii: S1878-8750(19)31064-2. doi: 10.1016/j.wneu.2019.04.072. [Epub ahead of print]

PMID:
31035019
6.

Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.

Cagney DN, Lamba N, Montoya S, Li P, Besse L, Martin AM, Brigell RH, Catalano PJ, Brown PD, Leone JP, Tanguturi SK, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA.

Breast Cancer Res Treat. 2019 Jul;176(1):171-179. doi: 10.1007/s10549-019-05236-6. Epub 2019 Apr 13.

PMID:
30982195
7.

Systemic Therapy of Central Nervous System Metastases of Breast Cancer.

Leone JP, Lin NU.

Curr Oncol Rep. 2019 Apr 8;21(6):49. doi: 10.1007/s11912-019-0802-6. Review. Erratum in: Curr Oncol Rep. 2019 May 17;21(7):59.

PMID:
30957209
8.

Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium.

Seano G, Nia HT, Emblem KE, Datta M, Ren J, Krishnan S, Kloepper J, Pinho MC, Ho WW, Ghosh M, Askoxylakis V, Ferraro GB, Riedemann L, Gerstner ER, Batchelor TT, Wen PY, Lin NU, Grodzinsky AJ, Fukumura D, Huang P, Baish JW, Padera TP, Munn LL, Jain RK.

Nat Biomed Eng. 2019 Mar;3(3):230-245. doi: 10.1038/s41551-018-0334-7. Epub 2019 Jan 7.

9.

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium.

J Clin Oncol. 2019 May 1;37(13):1081-1089. doi: 10.1200/JCO.18.01511. Epub 2019 Mar 12.

PMID:
30860945
10.

Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.

Garrido-Castro AC, Lin NU, Polyak K.

Cancer Discov. 2019 Feb;9(2):176-198. doi: 10.1158/2159-8290.CD-18-1177. Epub 2019 Jan 24. Review.

PMID:
30679171
11.

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.

Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, Winer EP, Lin NU, Wagle N.

Nat Genet. 2019 Feb;51(2):207-216. doi: 10.1038/s41588-018-0287-5. Epub 2018 Dec 10.

PMID:
30531871
12.

Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.

Metzger-Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz-Luis I, Hughes ME, Winer EP, Lin NU.

Oncologist. 2019 Jul;24(7):e441-e449. doi: 10.1634/theoncologist.2018-0363. Epub 2018 Dec 5.

PMID:
30518616
13.

Update on managing brain metastases in breast cancer.

Lin NU.

Clin Adv Hematol Oncol. 2018 Sep;16(9):598-601. Review. No abstract available.

PMID:
30256774
14.

Increasing Burden of Prior Authorizations in the Delivery of Oncology Care in the United States.

Lin NU, Bichkoff H, Hassett MJ.

J Oncol Pract. 2018 Sep;14(9):525-528. doi: 10.1200/JOP.18.00428. Epub 2018 Aug 20. No abstract available.

PMID:
30125129
15.

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer.

Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Jänne PA, Paweletz CP, Lin NU, Krop IE, Barry WT, Winer EP, Brown M, Jeselsohn R.

NPJ Breast Cancer. 2018 Aug 2;4:22. doi: 10.1038/s41523-018-0075-5. eCollection 2018.

16.

Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.

Natsuhara KH, Losk K, King TA, Lin NU, Camuso K, Golshan M, Pochebit S, Brock JE, Bunnell CA, Freedman RA.

Oncologist. 2019 May;24(5):595-602. doi: 10.1634/theoncologist.2018-0154. Epub 2018 Aug 3.

PMID:
30076279
17.

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update Summary.

Ramakrishna N, Temin S, Lin NU.

J Oncol Pract. 2018 Aug;14(8):505-507. doi: 10.1200/JOP.18.00291. Epub 2018 Jul 10. No abstract available.

PMID:
29989840
18.

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Kirshner JJ, Krop IE, Levinson J, Modi S, Patt DA, Perlmutter J, Winer EP, Lin NU.

J Clin Oncol. 2018 Sep 20;36(27):2804-2807. doi: 10.1200/JCO.2018.79.2713. Epub 2018 Jun 25.

PMID:
29939840
19.

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, Modi S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE.

J Clin Oncol. 2018 Sep 10;36(26):2736-2740. doi: 10.1200/JCO.2018.79.2697. Epub 2018 Jun 25.

PMID:
29939838
20.

Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer.

Cagney DN, Martin AM, Catalano PJ, Brown PD, Alexander BM, Lin NU, Aizer AA.

JAMA Oncol. 2018 Jul 1;4(7):1001-1003. doi: 10.1001/jamaoncol.2018.0813. No abstract available.

21.

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU.

NPJ Breast Cancer. 2018 May 4;4:10. doi: 10.1038/s41523-018-0060-z. eCollection 2018.

22.

Breast cancer-specific survival by age: Worse outcomes for the oldest patients.

Freedman RA, Keating NL, Lin NU, Winer EP, Vaz-Luis I, Lii J, Exman P, Barry WT.

Cancer. 2018 May 15;124(10):2184-2191. doi: 10.1002/cncr.31308. Epub 2018 Mar 2.

23.

Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?

Kabraji S, Ni J, Lin NU, Xie S, Winer EP, Zhao JJ.

Clin Cancer Res. 2018 Apr 15;24(8):1795-1804. doi: 10.1158/1078-0432.CCR-17-3351. Epub 2018 Feb 6.

24.

Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.

Poorvu PD, Vaz-Luis I, Freedman RA, Lin NU, Barry WT, Winer EP, Hassett MJ.

Breast Cancer Res Treat. 2018 Apr;168(3):727-737. doi: 10.1007/s10549-018-4659-4. Epub 2018 Jan 13.

PMID:
29332137
25.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY.

Lancet Oncol. 2018 Jan;19(1):e20-e32. doi: 10.1016/S1470-2045(17)30693-9. Review.

PMID:
29304358
26.

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA.

J Clin Oncol. 2018 Feb 20;36(6):543-553. doi: 10.1200/JCO.2017.76.0033. Epub 2018 Jan 3.

27.

Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.

Ferreira AR, Palha A, Correia L, Filipe P, Rodrigues V, Miranda A, André R, Fernandes J, Gouveia J, Passos-Coelho JL, Moreira A, Brito M, Ribeiro J, Metzger-Filho O, Lin NU, Costa L, Vaz-Luis I.

Breast. 2018 Feb;37:107-113. doi: 10.1016/j.breast.2017.11.003. Epub 2017 Nov 10.

PMID:
29131988
28.

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.

Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O'Connor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M.

Nat Commun. 2017 Nov 6;8(1):1324. doi: 10.1038/s41467-017-00965-y.

29.

Attitudes of patients with metastatic cancer towards research biopsies.

Robinson DH, Churilov L, Lin NU, Lim E, Seah D.

Asia Pac J Clin Oncol. 2018 Jun;14(3):231-238. doi: 10.1111/ajco.12783. Epub 2017 Nov 6.

PMID:
29106060
30.

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL.

J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2.

31.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.

Lin NU, Prowell T, Tan AR, Kozak M, Rosen O, Amiri-Kordestani L, White J, Sul J, Perkins L, Beal K, Gaynor R, Kim ES.

J Clin Oncol. 2017 Nov 20;35(33):3760-3773. doi: 10.1200/JCO.2017.74.0761. Epub 2017 Oct 2.

PMID:
28968165
32.

Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco type DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation.

Losk K, Freedman RA, Lin NU, Golshan M, Pochebit SM, Lester SC, Natsuhara K, Camuso K, King TA, Bunnell CA.

J Oncol Pract. 2017 Sep;13(9):e815-e820. doi: 10.1200/JOP.2017.023788. Epub 2017 Aug 31. Erratum in: J Oncol Pract. 2017 Nov;13(11):776.

PMID:
28858535
33.

Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies.

Ladas I, Fitarelli-Kiehl M, Song C, Adalsteinsson VA, Parsons HA, Lin NU, Wagle N, Makrigiorgos GM.

Clin Chem. 2017 Oct;63(10):1605-1613. doi: 10.1373/clinchem.2017.272849. Epub 2017 Jul 5.

34.

Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management.

Lin NU, Gaspar LE, Soffietti R.

Am Soc Clin Oncol Educ Book. 2017;37:45-56. doi: 10.14694/EDBK_175338.

PMID:
28561683
35.

Reply to Garcia J. et al.

Barroso-Sousa R, Lin NU.

Breast. 2017 Aug;34:132. doi: 10.1016/j.breast.2017.05.003. Epub 2017 May 11. No abstract available.

PMID:
28502743
36.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA.

Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review.

37.

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA.

Neuro Oncol. 2017 Oct 19;19(11):1511-1521. doi: 10.1093/neuonc/nox077.

38.

Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study.

Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA.

JAMA Oncol. 2017 Aug 1;3(8):1069-1077. doi: 10.1001/jamaoncol.2017.0001.

39.

Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.

Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I.

J Natl Compr Canc Netw. 2017 Mar;15(3):316-324.

PMID:
28275032
40.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group.

Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

41.

Prior Authorization for Medications in a Breast Oncology Practice: Navigation of a Complex Process.

Agarwal A, Freedman RA, Goicuria F, Rhinehart C, Murphy K, Kelly E, Mullaney E, St Amand M, Nguyen P, Lin NU.

J Oncol Pract. 2017 Apr;13(4):e273-e282. doi: 10.1200/JOP.2016.017756. Epub 2017 Feb 28.

PMID:
28245148
42.

Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study.

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA.

Oncologist. 2017 Apr;22(4):386-393. doi: 10.1634/theoncologist.2016-0369. Epub 2017 Feb 27.

43.

Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center.

Losk K, Vaz-Luis I, Camuso K, Batista R, Lloyd M, Tukenmez M, Golshan M, Lin NU, Bunnell CA.

J Natl Compr Canc Netw. 2016 Dec;14(12):1519-1526.

PMID:
27956536
44.

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, Ingle JN, Sukumar S, Wolff AC.

J Clin Oncol. 2017 Mar;35(7):751-758. doi: 10.1200/JCO.2015.66.2080. Epub 2016 Nov 21.

45.

Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.

Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso K, Metzger-Filho O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU.

Breast. 2016 Dec;30:136-140. doi: 10.1016/j.breast.2016.09.013. Epub 2016 Oct 6.

PMID:
27721193
46.

Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.

Bychkovsky BL, Guo H, Sutton J, Spring L, Faig J, Dagogo-Jack I, Battelli C, Houlihan MJ, Yeh TC, Come SE, Lin NU.

Oncologist. 2016 Dec;21(12):1495-1501. Epub 2016 Aug 22.

47.

Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.

Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA.

Breast Cancer Res Treat. 2016 Aug;159(1):151-62. doi: 10.1007/s10549-016-3927-4. Epub 2016 Aug 2.

PMID:
27484879
48.

Imaging in the evaluation and follow-up of early and advanced breast cancer: When, why, and how often?

Bychkovsky BL, Lin NU.

Breast. 2017 Feb;31:318-324. doi: 10.1016/j.breast.2016.06.017. Epub 2016 Jul 13. Review.

PMID:
27422453
49.

Updates in the management of brain metastases.

Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, Camidge DR, Vogelbaum MA, Dunn IF, Wen PY.

Neuro Oncol. 2016 Aug;18(8):1043-65. doi: 10.1093/neuonc/now127. Review.

50.

Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.

Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I.

Breast Cancer Res Treat. 2016 Jun;157(3):587-96. doi: 10.1007/s10549-016-3845-5. Epub 2016 Jun 6.

PMID:
27271765

Supplemental Content

Support Center